Russian Pharma Giant to Invest $80 Million in Pakistan for Insulin Plant
A Russian pharmaceutical company, Zavod Medsintez LLC, in partnership with Pakistan’s Genetics Pharmaceuticals, has announced an investment of approximately $80 million to establish insulin manufacturing facilities in Pakistan.
The project is aimed at strengthening the country’s healthcare infrastructure through local drug production.
This initiative is expected to reduce Pakistan’s reliance on imported insulin, which is essential for diabetes treatment. It also represents a significant step toward improving pharmaceutical self-sufficiency.
The project will be implemented in two phases over a period of six years. The first phase includes the establishment of an aseptic insulin filling facility with an estimated cost of $20 million, expected to be completed by December 2028.
The second phase involves the development of a full-scale insulin manufacturing plant with an investment of around $60 million, targeted for completion by December 2031.
Together, these phases aim to build a complete local insulin production system in Pakistan.
Once completed, the facility will enable Pakistan to produce insulin locally, including key formulations such as Rosinsulin variants.
This will significantly reduce reliance on imported medicines and strengthen the country’s pharmaceutical self-sufficiency in essential drugs.
The project also includes technology transfer and the development of Active Pharmaceutical Ingredient (API) production.
This will allow full-scale local manufacturing of insulin, from raw materials to finished products, improving supply stability, affordability.
The Drug Regulatory Authority of Pakistan (DRAP) has approved the project under strict compliance conditions, including defined timelines, quality assurance measures, and requirements for local production.
These regulations ensure accountability and adherence to pharmaceutical safety standards.
The investment is expected to boost foreign direct investment in Pakistan’s pharmaceutical sector.
It will also create employment opportunities and enhance domestic capacity for producing life-saving medicines, contributing to stronger healthcare infrastructure.
This investment aligns with Pakistan’s broader strategy to enhance domestic pharmaceutical production and reduce reliance on imported essential medicines, particularly in critical healthcare areas such as diabetes treatment.
It reflects ongoing efforts to strengthen national healthcare resilience and improve industrial capacity in the pharmaceutical sector.
With increasing diabetes cases, local insulin manufacturing is expected to improve availability and affordability for patients. It also supports long-term healthcare sustainability.
A Russian pharmaceutical company, Zavod Medsintez LLC, in partnership with Pakistan’s Genetics Pharmaceuticals, has announced an investment of approximately $80 million to establish insulin manufacturing facilities in Pakistan.
A Russian pharmaceutical company, Zavod Medsintez LLC, in partnership with Pakistan’s Genetics Pharmaceuticals, has announced an investment of approximately $80 million to establish insulin manufacturing facilities in Pakistan.
The project is aimed at strengthening the country’s healthcare infrastructure through local drug production.
This initiative is expected to reduce Pakistan’s reliance on imported insulin, which is essential for diabetes treatment. It also represents a significant step toward improving pharmaceutical self-sufficiency.
The project will be implemented in two phases over a period of six years. The first phase includes the establishment of an aseptic insulin filling facility with an estimated cost of $20 million, expected to be completed by December 2028.
The second phase involves the development of a full-scale insulin manufacturing plant with an investment of around $60 million, targeted for completion by December 2031.
Together, these phases aim to build a complete local insulin production system in Pakistan.
Once completed, the facility will enable Pakistan to produce insulin locally, including key formulations such as Rosinsulin variants.
This will significantly reduce reliance on imported medicines and strengthen the country’s pharmaceutical self-sufficiency in essential drugs.
The project also includes technology transfer and the development of Active Pharmaceutical Ingredient (API) production.
This will allow full-scale local manufacturing of insulin, from raw materials to finished products, improving supply stability, affordability.
The Drug Regulatory Authority of Pakistan (DRAP) has approved the project under strict compliance conditions, including defined timelines, quality assurance measures, and requirements for local production.
These regulations ensure accountability and adherence to pharmaceutical safety standards.
The investment is expected to boost foreign direct investment in Pakistan’s pharmaceutical sector.
It will also create employment opportunities and enhance domestic capacity for producing life-saving medicines, contributing to stronger healthcare infrastructure.
This investment aligns with Pakistan’s broader strategy to enhance domestic pharmaceutical production and reduce reliance on imported essential medicines, particularly in critical healthcare areas such as diabetes treatment.
It reflects ongoing efforts to strengthen national healthcare resilience and improve industrial capacity in the pharmaceutical sector.
With increasing diabetes cases, local insulin manufacturing is expected to improve availability and affordability for patients. It also supports long-term healthcare sustainability.
